Pavel Kapysh / Shutterstock.com
Canadian pharmaceutical company Bausch Health is suing Sandoz for patent infringement over its notice of intent to release a generic version of Xifaxan (rifaximin), Bausch’s irritable bowel syndrome (IBS) drug.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Bausch Health, Xifaxan, IBS, irritable bowel syndrome, rifaximin, Actavis, Teva, Sandoz, Novartis, Salix Pharmaceuticals, Alfasigma